No Data
No Data
TD Cowen Maintains Standard BioTools(LAB.US) With Buy Rating, Maintains Target Price $2.75
TD Cowen analyst Daniel Brennan maintains $Standard BioTools(LAB.US)$ with a buy rating, and maintains the target price at $2.75.According to TipRanks data, the analyst has a success rate of 58.3%
Standard BioTools (LAB) Receives a Buy From TD Cowen
Standard BioTools Outlines Strategic Vision and Financial Goals
Institutional Investors May Adopt Severe Steps After Standard BioTools Inc.'s (NASDAQ:LAB) Latest 9.2% Drop Adds to a Year Losses
Standard BioTools And 2 Other Penny Stocks Executives Are Buying
Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference